✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
SHR3162 is an investigational drug.
There have been 19 clinical trials for SHR3162. The most recent clinical trial was a Phase 1 trial, which was initiated on March 31st 2021.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Carcinoma, Ovarian Epithelial, and Breast Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd., and Fudan University.
There are two US patents protecting this investigational drug and twenty-one international patents.
Recent Clinical Trials for SHR3162
|A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer||Jiangsu HengRui Medicine Co., Ltd.||Phase 2|
|A Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)||Jiangsu HengRui Medicine Co., Ltd.||Phase 3|
|A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer||Jiangsu HengRui Medicine Co., Ltd.||Phase 1|
Top disease conditions for SHR3162
Top clinical trial sponsors for SHR3162
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|SHR3162||See Plans and Pricing||Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof||Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN)||See Plans and Pricing|
|SHR3162||See Plans and Pricing||Methods of using phthalazinone ketone derivatives||Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|SHR3162||Australia||AU2011288876||2030-08-09||See Plans and Pricing|
|SHR3162||Brazil||BR112013002220||2030-08-09||See Plans and Pricing|
|SHR3162||Canada||CA2806324||2030-08-09||See Plans and Pricing|
|SHR3162||China||CN102372716||2030-08-09||See Plans and Pricing|
|SHR3162||China||CN102686591||2030-08-09||See Plans and Pricing|
|SHR3162||European Patent Office||EP2604610||2030-08-09||See Plans and Pricing|
|SHR3162||Spain||ES2582315||2030-08-09||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|